Mamantia, Rejane .

HRN: 23-58-04  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/21/2023
AMPICILLIN 250MG (VIAL)
08/21/2023
08/28/2023
IV
120mg
Q12
Preterm, Potentially Septic
Waiting Final Action 
08/21/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
08/21/2023
08/28/2023
IV
18mg
Q24h
Preterm, Potentially Septic
Waiting Final Action 
08/31/2023
CEFTAZIDIME 1GM (VIAL)
08/31/2023
09/26/2023
IV
36mg
Q12
Sepsis
Checking Final Appropriateness 
08/31/2023
FLUCONAZOLE 2MG/ML, 100ML (VIAL)
08/31/2023
09/06/2023
IV
14mg As LD Then 7mg
OD
Sepsis
Checking Final Appropriateness 
08/31/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
08/31/2023
09/09/2023
IV
18mg As LD Then 9mg
Q12
Sepsis
Checking Final Appropriateness 
09/10/2023
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
09/10/2023
09/16/2023
IV
0.11mg/ml (1ml)
Q8hrs
Sepsis
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

 Indication:

              

 Type of Infection:

                             

           

 Compliance to guidelines:



 Initial appropriateness:



 If inappropriate:

           

 Final appropriateness:



 If inappropriate:

              

 Overall appropriateness: